Flavaglines as potent anticancer and cytoprotective agents

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 10064-10073

  Ribeiro, Nigel ^a   Thuaud, Frédéric ^a   Bernard, Yohann ^a   Gaiddon, Christian ^a   Cresteil, Thierry ^b   Hild, Audrey ^c,d,e   Hirsch, Etienne C ^c,d,e   Michel, Patrick Pierre ^c,d,e   Nebigil, Canan G ^a   Désaubry, Laurent ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLAVAGLINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROTECTION; DRUG SCREENING; DRUG SYNTHESIS; HEART PROTECTION; HUMAN; IC 50; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZOFURANS; BIOLOGICAL AGENTS; CARDIOTONIC AGENTS; CELLS, CULTURED; CISPLATIN; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DOXORUBICIN; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; NEOPLASMS; PARKINSON DISEASE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870044595     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301201z     Document Type: Article

References (33)

1. Ebada, S. S.; Lajkiewicz, N.; Porco, J. A., Jr.; Li-Weber, M.; Proksch, P. Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from Aglaia species (Meliaceae) Prog. Chem. Org. Nat. Prod. 2011, 94, 1-58
2. Ribeiro, N.; Thuaud, F.; Nebigil, C.; Desaubry, L. Recent advances in the biology and chemistry of the flavaglines Bioorg. Med. Chem. 2012, 20, 1857-1864
3. Bernard, Y.; Ribeiro, N.; Thuaud, F.; Türkeri, G.; Dirr, R.; Boulberdaa, M.; Nebigil, C.; Désaubry, L. Flavaglines Alleviate Doxorubicin Cardiotoxicity: Implication of Hsp27 Plos One 2011, 6, e25302
4. Fahrig, T.; Gerlach, I.; Horvath, E. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury Mol. Pharmacol. 2005, 67, 1544-1555
5. Bleumink, M.; Kohler, R.; Giaisi, M.; Proksch, P.; Krammer, P. H.; Li-Weber, M. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression Cell Death Differ. 2011, 18, 362-370
6. Giaisi, M.; Kohler, R.; Fulda, S.; Krammer, P. H.; Li-Weber, M. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas Int. J. Cancer 2012, 131, 1003-1008
7. Jin, C.; Rajabi, H.; Rodrigo, C. M.; Porco, J. A., Jr.; Kufe, D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein Oncogene 2012, 10.1038/onc.2012.236
8. Nasr, Z.; Robert, F.; Porco, J. A., Jr.; Muller, W. J.; Pelletier, J. eIF4F suppression in breast cancer affects maintenance and progression Oncogene 2012, 10.1038/onc.2012.105
9. Rodrigo, C. M.; Cencic, R.; Roche, S. P.; Pelletier, J.; Porco, J. A. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies J. Med. Chem. 2012, 55, 558-562
10. Schatz, J. H.; Oricchio, E.; Wolfe, A. L.; Jiang, M.; Linkov, I.; Maragulia, J.; Shi, W.; Zhang, Z.; Rajasekhar, V. K.; Pagano, N. C.; Porco, J. A., Jr.; Teruya-Feldstein, J.; Rosen, N.; Zelenetz, A. D.; Pelletier, J.; Wendel, H. G. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma J. Exp. Med. 2011, 208, 1799-1807
11. Thuaud, F.; Bernard, Y.; Turkeri, G.; Dirr, R.; Aubert, G.; Cresteil, T.; Baguet, A.; Tomasetto, C.; Svitkin, Y.; Sonenberg, N.; Nebigil, C. G.; Désaubry, L. Synthetic Analogue of Rocaglaol Displays a Potent and Selective Cytotoxicity in Cancer Cells: Involvement of Apoptosis Inducing Factor and Caspase-12 J. Med. Chem. 2009, 52, 5176-5187
12. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 2004, 56, 185-229
13. Gerard, B.; Jones, Ii, G.; Porco, J. A., Jr. A biomimetic approach to the rocaglamides employing photogeneration of oxidopyryliums derived from 3-hydroxyflavones J. Am. Chem. Soc. 2004, 126, 13620-13621
14. Roche, S. P.; Cencic, R.; Pelletier, J.; Porco, J. A., Jr. Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation Angew. Chem., Int. Ed. Engl. 2010, 49, 6533-6538
15. Davey, A. E.; Schaeffer, M. J.; Taylor, R. J. K. Synthesis of the novel anti-leukaemic tetrahydrocyclopenta[ b ]benzofuran, rocaglamide and related synthetic studies J. Chem. Soc., Perkin Trans. 1 1992, 2657-2666
16. Dobler, M. R.; Bruce, I.; Cederbaum, F.; Cooke, N. G.; Diorazio, L. J.; Hall, R. G.; Irving, E. Total synthesis of (±)-rocaglamide and some aryl analogues Tetrahedron Lett. 2001, 42, 8281-8284
17. Giglio, P.; Gilbert, M. R. Neurologic complications of cancer and its treatment Curr. Oncol. Rep. 2010, 12, 50-59
18. Gregg, R. W.; Molepo, J. M.; Monpetit, V. J.; Mikael, N. Z.; Redmond, D.; Gadia, M.; Stewart, D. J. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity J. Clin. Oncol. 1992, 10, 795-803
19. Bergamo, A.; Gaiddon, C.; Schellens, J. H.; Beijnen, J. H.; Sava, G. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates J. Inorg. Biochem. 2012, 106, 90-99
20. Meng, X.; Leyva, M. L.; Jenny, M.; Gross, I.; Benosman, S.; Fricker, B.; Harlepp, S.; Hebraud, P.; Boos, A.; Wlosik, P.; Bischoff, P.; Sirlin, C.; Pfeffer, M.; Loeffler, J. P.; Gaiddon, C. A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP Cancer Res. 2009, 69, 5458-5466
21. Benosman, S.; Gross, I.; Clarke, N.; Jochemsen, A. G.; Okamoto, K.; Loeffler, J. P.; Gaiddon, C. Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis Cell Death Differ. 2007, 14, 2047-2057
22. Thuaud, F.; Ribeiro, N.; Gaiddon, C.; Cresteil, T.; Desaubry, L. Novel Flavaglines Displaying Improved Cytotoxicity J. Med. Chem. 2010, 54, 411-415
23. Erlich, S.; Alexandrovich, A.; Shohami, E.; Pinkas-Kramarski, R. Rapamycin is a neuroprotective treatment for traumatic brain injury Neurobiol. Dis. 2007, 26, 86-93
24. Malagelada, C.; Jin, Z. H.; Jackson-Lewis, V.; Przedborski, S.; Greene, L. A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease J. Neurosci. 2010, 30, 1166-1175
25. Dong, F.; Guo, W.; Zhang, L.; Wu, S.; Teraishi, F.; Davis, J. J.; Fang, B. Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells Cancer Biol. Ther. 2006, 5, 165-170
26. Johnson, K.; Liu, L.; Majdzadeh, N.; Chavez, C.; Chin, P. C.; Morrison, B.; Wang, L.; Park, J.; Chugh, P.; Chen, H. M.; D'Mello, S. R. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs J. Neurochem. 2005, 93, 538-548
27. Weishaupt, J. H.; Kussmaul, L.; Grotsch, P.; Heckel, A.; Rohde, G.; Romig, H.; Bahr, M.; Gillardon, F. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction Mol. Cell. Neurosci. 2003, 24, 489-502
28. Faraco, G.; Pancani, T.; Formentini, L.; Mascagni, P.; Fossati, G.; Leoni, F.; Moroni, F.; Chiarugi, A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain Mol. Pharmacol. 2006, 70, 1876-1884
29. Bush, E. W.; McKinsey, T. A. Targeting histone deacetylases for heart failure Expert Opin. Ther. Targets 2009, 13, 767-784
30. Hahnen, E.; Hauke, J.; Trankle, C.; Eyupoglu, I. Y.; Wirth, B.; Blumcke, I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders Expert Opin. Invest. Drugs 2008, 17, 169-184
31. Mai, A.; Rotili, D.; Valente, S.; Kazantsev, A. G. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise Curr. Pharm. Des. 2009, 15, 3940-3957
32. Baumann, B.; Bohnenstengel, F.; Siegmund, D.; Wajant, H.; Weber, C.; Herr, I.; Debatin, K. M.; Proksch, P.; Wirth, T. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells J. Biol. Chem. 2002, 277, 44791-44800
33. Guerreiro, S.; Toulorge, D.; Hirsch, E.; Marien, M.; Sokoloff, P.; Michel, P. P. Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels Mol. Pharmacol. 2008, 74, 980-989